ANEW Medical (KLTO): Market Cap to Revenue Ratio
The flexibility of the Klotho Neurosciences Inc (KLTO) scientific team is ensured by the complete outsourcing of production and testing. The company's current P/S ratio clearly demonstrates the market valuation of the asset, where the current mark equals . Patents for the Klotho protein and investor support establish the fundamental base, however, the lack of revenue at the preclinical stage creates serious risks of a cash crunch.
Metric breakdowns and analytics for Klotho Neurosciences Inc (KLTO)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Klotho Neurosciences Inc|KLTO - Long-Term Debt to Equity|Current Liabilities to Capital anewmeds.com|KLTO - Company Debts|Debts to Net Assets ANEW Medical, Inc.|KLTO - Company Long-Term Debts|Company Current Liabilities Klotho Neurosciences|Interim Coverage Ratio anewmeds.com
- earnings and multiples data:
KLTO - Net Profit|Expected Net Profit Klotho Neurosciences Inc|KLTO - Price to Earnings Ratio|Price to Future Earnings Ratio anewmeds.com|KLTO - PEG Multiple|Enterprise Value to EBITDA Ratio ANEW Medical, Inc.|KLTO - Operating profit EBITDA|Net earnings per one share for the last twelve months Klotho Neurosciences|KLTO - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months anewmeds.com|KLTO - Net earnings per share growth this year|Expected earnings per share trend next year Klotho Neurosciences Inc
- sales revenue and business income indicators:
Fundamental company analysis:KLTO, ANEW Medical
The P/S ratio determines the market value of a business relative to its revenue, serving as a key tool for assessing revenue generation efficiency. This multiple compares total market capitalization with sales volume to reveal the extent of the asset's overvaluation. By analyzing the price-to-sales multiple history, an investor can track the dynamics of market expectations. For Klotho Neurosciences Inc (KLTO), the growth of this metric is driven by the potential of the Klotho protein in Alzheimer's therapy and the influx of strategic capital.
Competing companies
BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC: Market Cap to Revenue Ratio|Axsome Therapeutics Inc - P/S Multiple|Price to Sales ACADIA Corp|XENE (Xenon Pharmaceuticals) - Market Cap to Revenue|vikingtherapeutics.com (VKTX) - P/S Multiple|Price-to-Revenue Ratio Supernus|CPRX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY - Price to Sales|Price-to-Revenue Ratio Biohaven Ltd. BHVN|Price-to-Revenue Coefficient amylyx.com (AMLX)|Trevi Therapeutics, Inc. - P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Market Cap to Revenue|AVXL: P/S Multiple|CBLL - Price-to-Revenue Coefficient|PRTA (Prothena Biosciences) - P/S Multiple|Price to Sales Alector Therapeutics ALEC|Price-to-Revenue Ratio Annexon (ANNX)|omeros.com - Market Cap to Revenue Ratio|P/S Multiple NGNE (Neurogene Corp)|ACIU - Market Cap to Revenue|Voyager Therapeutics - P/S Multiple|Price to Sales neumoratx.com|Scilex (SCLX) - Price-to-Revenue Ratio|TVGN - Price-to-Revenue Coefficient|Market Cap to Revenue ACOG|CGTX: Market Capitalization-to-Revenue Ratio|P/S Multiple IKT|Price-to-Revenue Coefficient cassavasciences.com|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VistaGen Therapeutics Inc - P/S Multiple|Ovid Therapeutics Inc. (OVID) - Market Cap to Revenue|Acumen Pharmaceuticals (ABOS) - Price-to-Revenue Ratio|cervomed.com (CRVO) - P/S Multiple|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Price-to-Revenue Ratio CLNN|Market Cap to Revenue PEPG (PepGen Inc.)|Market Cap to Sales Volume JUNS|Price-to-Revenue Ratio Relmada Therapeutics RLMD|annovisbio.com (ANVS) - Price to Sales|GRCE - Price-to-Revenue Ratio|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Revenue Ratio|NRSN: P/S Multiple|Price to Sales Reviva Pharmaceuticals, Inc. (RVPH)|Market Cap to Revenue MTVA|P/S Multiple neuraxis.com|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG (passagebio.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|Minerva (NERV) - Price to Sales|ATHA - Price-to-Revenue Ratio|ADXN - P/S Multiple|alzamend.com (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Price to Sales Pasithea KTTA|Market Cap to Revenue CRGT (Cortigent, Inc.)|Market Cap to Sales Volume ATXI|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Market Capitalization-to-Revenue Ratio CARA|CHRO - Price-to-Revenue Ratio|Price to Sales Eliem Therapeutics|ITCI (intracellulartherapies.com) - Market Cap to Revenue|longboardpharma.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|Market Cap to Revenue Ratio NKGN (NKGen Biotech Inc)|P/S Multiple NRBO|SAGE - Price to Sales|Synaptogenix, Inc. - Market Cap to Revenue|P/S Multiple trevena.com TRVN|VIGL - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio WENA (anewmeds.com)|Cerevel (CERE) - Price-to-Revenue Ratio
